Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oncothyreon -- Ignore unavailable to you. Want to Upgrade?

To: StockMiser who wrote (588)	4/22/1999 8:50:00 AM
From: Phil Cressman	Read Replies (1) \| Respond to of 2344

I have held Biomira for over four years now and while development has not proceeded as rapidly as hoped there has been nothing negative about this company's development program. My personal involvement with breast cancer during my wife's treatment program convinced me that immune enhancement therapy is going to be one of the most significant advances in cancer therapy. It may take two more years before Biomira gets full acceptance but the potential benefit to cancer patients is a dividend far more valuable to me than a doubling or tripling of the stock price.